医学
肿瘤科
髓系白血病
内科学
不利影响
队列
总体生存率
髓样
下调和上调
生物信息学
队列研究
预测模型
比例危险模型
白血病
生存分析
靶向治疗
疾病
回顾性队列研究
血液学
观察研究
作者
Yaming Zhang,Min Zhang,Yali Huang,Junzhao Wan,Ping Liu,Ping Wang,Zhen Zhou,Fangya Hu,Jianta Wang,Dan Ma,Qian Kang
标识
DOI:10.3389/fonc.2026.1780304
摘要
Introduction ASXL1 is a frequently mutated gene in acute myeloid leukemia (AML) and is clinically recognized as an adverse prognostic marker, yet its clinical impact remains markedly heterogeneous. Methods Utilizing the BeatAML cohort, we integrated genomic, transcriptomic, immunophenotypic, and drug-sensitivity data to delineate this variability. Results Although ASXL1 mutations remained an independent adverse factor in multivariable analyses, survival outcomes did not differ significantly between ASXL1 -mutated patients and those lacking other high-risk lesions after excluding co-occurring adverse mutations, suggesting that ASXL1 status alone does not uniformly dictate prognosis. By stratifying ASXL1 -mutated patients based on treatment response, we identified two biologically distinct subsets-complete remission (CR) versus relapsed/refractory (R/R)-characterized by divergent clinical outcomes. Comparative analyses revealed distinct transcriptional profiles, including upregulated MAP3K15 expression in ASXL1 -mutated cases, alongside consistent immunophenotypic downregulation of CD11b, CD123, and HLA-DR in R/R patients. Leveraging these routinely measured markers, we developed a three-parameter ImmuScore that robustly stratified prognosis in both the BeatAML cohort and an independent clinical validation set. Importantly, the ImmuScore captured functional drug-response patterns: patients with low scores displayed significantly higher Z-scores-indicating reduced sensitivity across multiple chemotherapeutic and targeted agents. Discussion These findings link immunophenotypic signatures to therapeutic vulnerability, providing a mechanistic explanation for treatment failure in a subset of ASXL1 -mutated AML. To address potential small-sample bias, Firth penalized regression was applied. Collectively, this study demonstrates that ASXL1 -mutated AML is not a monolithic high-risk entity. The ImmuScore provides a biologically informed and clinically feasible tool to identify truly high-risk ASXL1 -mutated patients, potentially guiding personalized therapeutic strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI